This is a news story, published by Investor's Business Daily, that relates primarily to Hims & Hers news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Medical Stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest loss drugs Ozempic news, Novo Nordisk news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Loss Drug MarketInvestor's Business Daily
•Health
Health
67% Informative
Compounding pharmacy Hims & Hers stock plunges 24% in morning trades.
The company plans to skirt the FDA 's decision by selling doses of semaglutide that Novo Nordisk doesn't sell.
Hims expects $725 million in sales from weight-loss drugs this year .
The outlook includes personalized versions of Novo 's popular diabetes drug Ozempic.
VR Score
62
Informative language
64
Neutral language
3
Article tone
formal
Language
English
Language complexity
39
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Source diversity
2
Affiliate links
no affiliate links
Small business owner?
